U.K.’s Cost-Effectiveness Watchdog NICE Says No To Alzheimer’s Drug Leqembi
The U.K. regulatory authority approved the Alzheimer's disease drug, Leqembi, last month. But the U.K. cost-effectiveness watchdog NICE recommends against reimbursement.
The U.K. regulatory authority approved the Alzheimer's disease drug, Leqembi, last month. But the U.K. cost-effectiveness watchdog NICE recommends against reimbursement.
What's Your Reaction?
